Core Insights - Idexx Laboratories reported revenue of 954.29millionforthequarterendedDecember2024,reflectingayear−over−yearincreaseof5.8936.78 million by 1.87% [1] - The company's EPS for the quarter was 2.62,upfrom2.32 in the same quarter last year, surpassing the consensus EPS estimate of 2.40by9.17574.10 million, exceeding the two-analyst average estimate of 564.74million,withayear−over−yearchangeof+4.4296.37 million, surpassing the two-analyst average estimate of 286.18million,withayear−over−yearchangeof+9.228.15 million, compared to the 25.71millionaverageestimate,representingayear−over−yearchangeof+1.123.14 million, slightly below the 23.49millionaverageestimate,withayear−over−yearchangeof+5.7870.47 million, exceeding the five-analyst average estimate of 854.04million,withayear−over−yearchangeof+64.11 million, below the 5.80millionestimatedbyfiveanalysts,representingayear−over−yeardeclineof−28.734.56 million, exceeding the 31.09millionaverageestimate,withayear−over−yearchangeof+5.445.15 million, slightly below the five-analyst average estimate of $45.63 million, with a year-over-year change of +8.1% [4] Stock Performance - Idexx shares returned +1.6% over the past month, compared to the Zacks S&P 500 composite's +2.7% change, indicating potential underperformance in the near term with a Zacks Rank 4 (Sell) [3]